Публикации

     Golikova, Firsov, Strukova, Portnoy. patent №2787393 "MODIFIED IN VITRO DYNAMIC MODEL (M-DS) FOR PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES WITH ANTIMICROBIAL AGENTS", 2022 (перевод)
Alieva K.N., Golikova M.V., Portnoy Y.A., Firsov A.A. Antibiotic Combinations Preventing Bacterial Resistance: Studies on an in vitro Model with Staphylococcus aureus Exposed to Linezolid–Daptomycin. Antibiotics and Chemotherapy. 2019;64(9-10):8-13. (In Russ.) https://doi.org/10.24411/0235-2990-2019-10050 (перевод).
Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA. Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures. J Chemother. 2019, 31:252-260. https://doi.org/10.1080/1120009X.2019.1623361.
Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA. A novel parameter to predict the effects of antibiotic combinations on the development of Staphylococcus aureus resistance: in vitro model studies at subtherapeutic daptomycin and rifampicin exposures. J Chemother. 2019, 31(6):320-328. https://doi.org/10.1080/1120009X.2019.1640924.
Golikova MV, Strukova EN, Portnoy YA, Zinner SH, Firsov AA. Predicting the antistaphylococcal effects of daptomycin–rifampicin combinations in an in vitro dynamic model. J. Antibiotics. 2020. 73(2):101-107. https://doi.org/10.1038/s41429-019-0249-x.
Maria V. Golikova, Elena N. Strukova, Yury A. Portnoy, Stephen H. Zinner, Alexander A. Firsov. Verification of a novel approach to predicting effects of antibiotic combinations: in vitro dynamic model study with daptomycin and gentamicin against Staphylococcus aureus. Antibiotics 2020, 9, 538. https://doi.org/10.3390/antibiotics9090538.
SH Zinner, KN Alieva, MV Golikova, EN Strukova, YA Portnoy, AA Firsov. Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin. J Antimicrob Chemother. 2020. https://doi.org/10.1093/jac/dkab095/6256239.
Golikova, M.V.; Strukova, E.N.; Portnoy, Y.A.; Zinner, S.H.; Firsov, A.A. MPC-Based Prediction of Anti-Mutant Effectiveness of Antibiotic Combinations: In Vitro Model Study with Daptomycin and Gentamicin against Staphylococcus aureus. Antibiotics 2021, 10, 1148. https://doi.org/10.3390/antibiotics10101148.
Filimonova, A.V.; Golikova, M.V.; Strukova, E.N.; Portnoy, Y.A.; Kuznetsova, A.A.; Zinner, S.H. Predicting the Effects of Carbapenem/Carbapenemase Inhibitor Combinations against KPC-Producing Klebsiella pneumoniae in Time-Kill Experiments: Alternative versus Traditional Approaches to MIC Determination. Antibiotics 2021, 10, 1520. https://doi.org/10.3390/antibiotics10121520.
Golikova MV, Alieva KN, Filimonova AV, Ageevets VA, Sulian OS, Avdeeva AA, Sidorenko SV, Zinner SH. Klebsiella pneumoniae Susceptibility to Carbapenem/Relebactam Combinations: Influence of Inoculum Density and Carbapenem-to-Inhibitor Concentration Ratio. Biomedicines. 2022;10(6):1454. https://doi.org/10.3390/biomedicines10061454.
Alieva KN, Golikova MV, Dovzhenko SA, Kobrin MB, Strukova EN, Ageevets VA, Avdeeva AA, Sulian OS, Sidorenko SV, Zinner SH. Testing the mutant selection window hypothesis with meropenem: In vitro model study with OXA-48-producing Klebsiella pneumoniae. PLoS One. 2023 Aug 4;18(8):e0288660. doi: 10.1371/journal.pone.0288660.
Golikova MV, Strukova EN, Alieva KN, Ageevets VA, Avdeeva AA, Sulian OS, Zinner SH. Meropenem MICs at Standard and High Inocula and Mutant Prevention Concentration Inter-Relations: Comparative Study with Non-Carbapenemase-Producing and OXA-48-, KPC- and NDM-Producing Klebsiella pneumoniae. Antibiotics (Basel). 2023 May 8;12(5):872. doi: 10.3390/antibiotics12050872.
Alieva, K.N.; Golikova, M.V.; Kuznetsova, A.A.; Zinner, S.H. Fluorescence Microscopy: Determination of Meropenem Activity against Klebsiella pneumoniae. Antibiotics 2023, 12, 1170. https://doi.org/10.3390/antibiotics12071170.
Golikova MV, Alieva KN, Strukova EN, Kondratieva DA, Petrova NF, Petrova MA, Zinner SH. Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model. Antibiotics (Basel). 2023 Dec 12;12(12):1717. doi: 10.3390/antibiotics12121717.